Liver X receptors (LXRs) are nuclear receptors that function as master regulators of cholesterol homeostasis and lipid metabolism. There are two LXR isoforms: LXRα (NR1H3) and LXRβ (NR1H2), which are ligand-activated transcription factors that sense oxysterols and regulate genes involved in cholesterol efflux, metabolism, inflammation, and brain function. LXRs have emerged as important therapeutic targets for neurodegenerative diseases due to their ability to modulate cholesterol metabolism, reduce neuroinflammation, and promote amyloid clearance in the brain.
LXR proteins have the typical nuclear receptor architecture:
| Isoform |
Gene |
Amino Acids |
Expression Pattern |
| LXRα |
NR1H3 |
447 aa |
Liver, adipose, intestine, brain |
| LXRβ |
NR1H2 |
460 aa |
Ubiquitous (all tissues) |
¶ Domain Architecture
LXR Protein Structure
┌────────────────────────────────────────────────────────┐
│ AF-1 │ DBD │ Hinge │ LBD │ AF-2 │
│ (1-120) │(121-200)│ (201-260) │ (261-420) │(421-447)│
└────────────────────────────────────────────────────────┘
DBD: DNA-binding domain (zinc fingers)
LBD: Ligand-binding domain (hydrophobic pocket)
AF: Activation function
- N-terminal AF-1 Domain: Variable, confers isoform-specific transcriptional activation
- DNA-binding Domain (DBD): Contains two C4-type zinc fingers that bind to DR-4 response elements
- Hinge Region: Flexible linker allowing conformational changes
- Ligand-binding Domain (LBD): Hydrophobic pocket binds oxysterols and synthetic agonists
- AF-2 Region: Helix 12 that completes the agonist-bound conformation
LXRs are the body's primary cholesterol sensors:
-
Cholesterol Efflux Regulation:
- Activate ABCA1: Promotes ApoE lipidation and cholesterol efflux to ApoA1
- Activate ABCG1: Mediates cholesterol efflux to HDL
- Activate ABCG4: Brain-specific cholesterol efflux
-
Cholesterol Transport:
- Regulate APOE expression in brain
- Control CYP7A1 (cholesterol 7α-hydroxylase) in liver
- Modulate LDL receptor expression
LXRs have profound anti-inflammatory properties:
- Transrepression: Inhibit NF-κB transcription without DNA binding
- COX-2 Suppression: Reduce prostaglandin synthesis
- iNOS Inhibition: Decrease nitric oxide production
- Cytokine Regulation: Modulate IL-1β, TNF-α, IL-6 expression
- Fatty Acid Synthesis: Activate SREBP-1c for lipogenesis
- Triglyceride Regulation: Modulate lipogenic gene expression
- Phospholipid Metabolism: Control lipid composition
LXRs are particularly important in AD pathogenesis:
Amyloid Pathology:
- LXR agonists reduce amyloid-β deposition in mouse models
- ABCA1/LXR pathway affects APOE lipidation and Aβ clearance
- Enhanced microglial cholesterol efflux reduces amyloid burden
Cognitive Function:
- LXR activation improves memory in AD models
- Synaptic protection through cholesterol regulation
- Neuroinflammatory reduction
Therapeutic Implications:
- LXR agonists (GW3965, T0901317) show promise in preclinical studies
- Selective LXRβ agonists avoid peripheral side effects
- ABCA1 activators as alternative approach
LXR activation provides neuroprotection in PD:
Dopaminergic Neuron Protection:
- Reduced oxidative stress in substantia nigra
- Enhanced mitochondrial function
- Anti-apoptotic effects
Neuroinflammation:
- Suppression of microglial activation
- Reduced dopaminergic neuron loss
- Modulation of glial cell function
Potential Therapeutics:
- LXR agonists protect against MPTP toxicity
- GW3965 reduces neuroinflammation
- Combined approach with L-DOPA
- Modulation of lipid metabolism in motor neurons
- Anti-inflammatory effects
- Energy metabolism support
- Cholesterol regulation in neurons
- Neuroinflammatory pathways
- Lipid droplet metabolism
| Gene Variant |
Effect |
Disease Association |
| NR1H3 (LXRα) variants |
Altered activity |
AD, MS risk |
| NR1H2 (LXRβ) variants |
Modified function |
Neuroprotection |
| ABCA1 variants |
Cholesterol efflux |
AD risk |
| Partner |
Interaction Type |
Function |
| RXR |
Heterodimer formation |
DNA binding |
| PGC-1α |
Coactivator |
Transcriptional activation |
| NCoR/SMRT |
Corepressor |
Silencing in absence of ligand |
| ABCA1 |
Target gene |
Cholesterol efflux |
| APOE |
Target gene |
Lipidation |
- PPAR Pathway: Cross-activation with PPARγ
- SREBP Pathway: Coordinate lipid regulation
- NF-κB: Reciprocal repression
- Neurons: High expression, particularly in cortex and hippocampus
- Astrocytes: Moderate to high expression
- Microglia: LXRβ predominant, increases with activation
- Oligodendrocytes: Lower expression
- Ligand-dependent: Activated by oxysterols
- Cholesterol levels: Feedback regulation
- Inflammatory signals: NF-κB suppresses LXR activity
-
GW3965: Widely used research agonist
- Good brain penetration
- Reduces amyloid pathology
- Improves cognition
-
T0901317: Potent LXR agonist
- Strong cholesterol efflux effect
- Liver toxicity concerns
-
LXR-623 (Way-254011): Selective LXRβ
- Reduced liver side effects
- Clinical trials for atherosclerosis
¶ Challenges and Solutions
- Peripheral Side Effects: Selective LXRβ agonists
- Lipogenesis: Tissue-specific delivery
- Brain Penetration: Optimized compounds
- ABCA1 Direct Activators: Avoid LXR side effects
- Gene Therapy: Target ABCA1 expression
- APOE Modulators: Enhance lipidation